IL6 and rheumatoid arthritis: The availability of new effective drugs that are able to modulate the inflammatory cascade of RA is another factor that contributes to this “change of perspective” in RA treatment; these drugs are generally known as bio(techno)logical agents and may target TNF [15], CD20+ cells [16], IL-6 [17], and T-cells costimulation [18].